Advertisement

Topics

PubMed Journals Articles About "Efficacy Safety Dual Bronchodilator Combination Umeclidinium Vilanterol COPD" RSS

12:07 EDT 20th June 2019 | BioPortfolio

Efficacy Safety Dual Bronchodilator Combination Umeclidinium Vilanterol COPD PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Efficacy Safety Dual Bronchodilator Combination Umeclidinium Vilanterol COPD articles that have been published worldwide.

More Information about "Efficacy Safety Dual Bronchodilator Combination Umeclidinium Vilanterol COPD" on BioPortfolio

We have published hundreds of Efficacy Safety Dual Bronchodilator Combination Umeclidinium Vilanterol COPD news stories on BioPortfolio along with dozens of Efficacy Safety Dual Bronchodilator Combination Umeclidinium Vilanterol COPD Clinical Trials and PubMed Articles about Efficacy Safety Dual Bronchodilator Combination Umeclidinium Vilanterol COPD for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Efficacy Safety Dual Bronchodilator Combination Umeclidinium Vilanterol COPD Companies in our database. You can also find out about relevant Efficacy Safety Dual Bronchodilator Combination Umeclidinium Vilanterol COPD Drugs and Medications on this site too.

Showing "Efficacy safety dual bronchodilator combination umeclidinium vilanterol COPD" PubMed Articles 1–25 of 13,000+

Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.

Elderly patients with chronic obstructive pulmonary disease (COPD) and those with more severe airway limitation are perceived to experience reduced efficacy from inhaled bronchodilators, especially those administered in a dry powder inhaler. This study compared the efficacy and safety of a long-acting muscarinic antagonist/long-acting β-agonist dry powder combination in elderly patients with COPD and patients with moderate-to-very severe airflow limitation.


Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults.

The pharmacokinetics (PK) and safety of single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) after single and repeat dosing in healthy Chinese adults were assessed. In this open-label study (NCT02837380), subjects received once-daily FF/UMEC/VI 100/62.5/25 μg on day 1 and repeat doses on days 2-7. PK parameters (days 1 and 7) included maximum observed concentration (C ) and area under the plasma concentration-time curve (AUC) from time zero (predose) to last time of quantifiable concent...

Combined FEV1 and FVC Bronchodilator Response, Exacerbations, and Mortality in COPD.

The American Thoracic Society/European Respiratory Society defines a positive bronchodilator response (BDR) by a composite of BDR in either FEV1 and/or FVC ≥12% and 200ml (ATS-BDR). We hypothesized that ATS-BDR components would be differentially associated with important COPD outcomes.


Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.

Ensifentrine (RPL554), an inhaled 'bifunctional' dual phosphodiesterase 3/4 inhibitor that exhibits both bronchodilator and anti-inflammatory activities, provides a new option in the treatment of chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases that are under clinical development. Ensifentrine appears to be initially under development for the treatment of COPD although it is not yet clear whether it should be understood as an add-on therapy in patients for the treatment o...

Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study.

An artificial-tear formulation containing the dual polymers hydroxypropyl guar (HPG) and hyaluronic acid (HA) is approved for the treatment of dry-eye disease (DED). The present study compared the efficacy and safety of the HPG-HA dual-polymer formulation vs a sodium hyaluronate (SH)-containing artificial-tear formulation in patients with DED.

Benralizumab for the Prevention of COPD Exacerbations.

The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.

ACO: Time to move from the description of different phenotypes to the treatable traits.

Asthma-COPD overlap (ACO) is a term that encompasses patients with characteristics of two conditions, smoking asthmatics or COPD patients with asthma-like features such as high bronchodilator response or blood eosinophil count ≥300 cells/μL. The aim of this study was to compare the different phenotypes inside the ACO definition in a real-life population cohort.

Multicenter, Randomized, Double-Blind, Parallel, Active Control, Phase III Clinical Study to Assess the Efficacy and Safety of THVD-201 (Combination of Tolterodine and Pilocarpine) in Patients with Overactive Bladder Including an Open-Label, Extension Study.

We evaluated efficacy and safety of THVD-201, which is a combination of tolterodine 2 mg and pilocarpine 9 mg, vs. tolterodine monotherapy in overactive bladder patients.

Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.

Combination therapy based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an emerging trend in cancer treatment, but the clinical value of EGFR-TKIs combination therapy remains controversial. Thus, we conducted a comprehensive analysis of randomized controlled trials (RCTs) comparing EGFR-TKIs combination therapies with monotherapies, aiming to evaluate the safety and efficacy of EGFR-TKIs based combination therapy and to find a more beneficial combination strategy.

Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.

Revefenacin, a novel, lung-selective, long-acting muscarinic antagonist, has been developed for nebulized therapy for chronic obstructive pulmonary disease (COPD). We present the results of replicate Phase III efficacy and safety studies of revefenacin in patients with moderate to very severe COPD.

A web-based physical activity intervention benefits persons with low self-efficacy in COPD: results from a randomized controlled trial.

Promoting physical activity (PA) is of top priority in chronic obstructive pulmonary disease (COPD). This study examines the influence of an internet-delivered intervention on the relationship between exercise self-efficacy and changes in PA, physical health, and exercise capacity in COPD. 112 U.S. Veterans with COPD were randomized to either a comparison (pedometer alone) or an intervention group (pedometer plus access to an internet-mediated PA intervention). There was a significant interaction between ba...

Improved Treatment Outcome of Pembrolizumab in Patients with Non-small Cell Lung Cancer and Chronic Obstructive Pulmonary Disease.

Emerging immune profiling data suggest a higher sensitivity to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD), compared with those without COPD. This study aimed to investigate the clinical impact of COPD on the treatment response to ICIs in a large number of patients with NSCLC. In total, 133 patients with spirometry test results were retrospectively identified among those who received palliative pembrolizumab for NSCLC. ...

Obesity in COPD: Comorbidities with Practical Consequences?

COPD and obesity often coexist and there is a complex interaction between them. Our aim was to evaluate the prevalence of obesity in a secondary care COPD population. Furthermore, the presence of comorbidities in obese (COPD) and non-obese COPD (COPD) individuals was studied. In 1654 COPD patients (aged ≥18 years) who visited a pulmonologist between January 2015 and December 2015, patient characteristics, pulmonary function tests and comorbidities were obtained from the medical records. Subjects were cate...

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease.

Studies report that up to 80% of individuals with chronic obstructive pulmonary disease (COPD) may struggle with symptoms of depression. However, this major comorbidity in COPD is rarely managed effectively. A number of recent studies indicate that left untreated, COPD-related depression is associated with worse quality of life, worse compliance with COPD treatment plan, increased exacerbations, hospital admissions, and healthcare costs when compared to individuals with COPD without depression. Regrettably,...

Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials.

To assess the efficacy and tolerability of dual combination of blood pressure (BP)-lowering drugs as initial treatment for hypertension.

A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease.

Effects of Tiotropium Combined with Theophylline on Stable COPD Patients of Group B, D and its Impact on Small Airway Function: A Randomized Controlled Trial.

Tiotropium bromide has been widely used in clinical practice, while theophylline is another treatment option for chronic obstructive pulmonary disease (COPD). However, only a few relevant studies have investigated the long-term outcomes and efficacy of both in patients with COPD. We evaluated the effects of tiotropium and low-dose theophylline on stable COPD patients of groups B and D.

Traditional Chinese medicine classic herbal formula Xiaoqinglong decoction for acute exacerbation of chronic obstructive pulmonary disease: A systematic review protocol.

Xiaoqinglong decoction (XQLD) is 1 of the traditional Chinese medicine (TCM) classic herbal formula that is widely used in Asian for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). In recent years, there has been increasing interest in the use of XQLD to treat COPD in China. So it is necessary to update the research and re-evaluate the efficacy and safety of XQLD to provide up-to-date evidence for COPD management. Therefore, we provide a protocol for a systematic review of XQLD for COP...

Efficacy of Disease Management Programs Asthma and COPD? Results of a Cross-Sectional Study.

 The efficacy of the German disease management programs (DMP) asthma and chronic obstructive pulmonary disease (COPD) cannot be shown with the legally bound documentations. Studies with control groups are rare. Aim of this work was to investigate in a cross-sectional study whether the disease control differs in participants (DMP+) and non-participants (DMP-) of the DMPs asthma and COPD.

An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup.

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous smoking-related disease characterized by airway obstruction and inflammation. This inflammation may persist even after smoking cessation and responds variably to corticosteroids. Personalizing treatment to biologically similar "molecular phenotypes" may improve therapeutic efficacy in COPD. IL-17A is involved in neutrophilic inflammation and corticosteroid resistance, and thus may be particularly important in a COPD molecular phenotype.

EMS Lithoclast Trilogy™: an effective single-probe dual-energy lithotripter for mini and standard PCNL.

Several energy sources are available to clear stones during PCNL. Required improvements are faster stone clearance, optimized suction and ease of use while maintaining high patient safety standard. EMS LithoClast Trilogy, is the first device combining electromagnetic impactor with ultrasonic energy and suction, all-in-one probe. Animal studies and in vitro phantom stone studies have proven safety and efficacy of this device. We aim to study safety and clinical efficacy of Trilogy in our patients.

Safety and Tolerability of Comprehensive Research Bronchoscopy in COPD: Results from the SPIROMICS Bronchoscopy Sub-Study.

There is an unmet need to investigate the lower airways in chronic obstructive pulmonary disease (COPD) to define pathogenesis and to identify potential markers to accelerate therapeutic development. Although bronchoscopy is well-established to sample airways in various conditions, a comprehensive COPD research protocol is not currently published.

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.

Evaluate the efficacy and safety of dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab, a monoclonal IgG1 antibody, in addition to certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA) and inadequate response (IR) to certolizumab pegol.

Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.

Triple versus Dual Inhaler therapy in moderate-to-severe COPD: A systematic review and meta-analysis of randomized controlled trials.

Treatment of COPD is evolving specially with triple inhaler therapy.


Advertisement
Quick Search
Advertisement
Advertisement